期刊文献+

调脂舒脉方治疗高脂血症气阴两虚证40例疗效观察 被引量:1

Treatment of Hyperlipemia with Deficiency of Qi and Yin syndrome by Tiaozhi Shumai Fang: An Observation of 40 Cases
下载PDF
导出
摘要 目的:观察调脂舒脉方治疗高脂血症气阴两虚证的疗效。方法:将80例患者随机分为2组各40例。治疗组口服调脂舒脉方(由黄芪、山茱萸、沙参、白术、当归、郁金、地龙、荷叶、川芎、生地黄、红花等组成)治疗,对照组口服多烯康胶丸治疗。2组均以1月为1疗程。主要观察临床疗效、治疗前后症状积分及血脂各项指标的变化。结果:总有效率治疗组为92.5%,对照组为72.5%,2组比较,差异有非常显著性意义(P<0.01),提示治疗组疗效明显优于对照组。结论:调脂舒脉方对高脂血症气阴两虚证者有较好的治疗作用。 Objective: To observe the curative effect of Tiaozhi Shumai Fang (TSF) for hyperlipemia with deficiency of qi and yin syndrome. Methods: 80 cases were allocated to treatment group and control group(each group 40 cases) randomly. The treatment group was treated by TSF(composed of Radix Astragali, Fructus Corni, Radix Adenophorae, Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Radix Curcumae, Pheretima, Folium Nelumbi-nis, Rhizoma Chuanxiong, Radix Rehmanniae and Flos Carthama, etc. ), and control group by epanol pill. One month constituted a course of treatment. The clinical curative effect, scoring of symp-toms and various indexes of blood - lipid were observed before and after treatment. Results: The total effective rate was 92.5% in treatment group, and 72. 5% in control group( P<0.01). Con-clusion: TSF possesses a good curative effect for hyperlipemia with deficiency of qi and yin syndrome.
出处 《新中医》 CAS 北大核心 2004年第9期22-23,共2页 New Chinese Medicine
基金 广东省中医药管理局科研基金资助项目(编号:103162)
关键词 高脂血症 气阴两虚 调脂舒脉方 hyperlipemia both deficiency of qi and yin Tiaozhi Shumai Fang
  • 相关文献

参考文献2

  • 1中华人民共和国卫生部.中药新药临床研究指导原则·第2辑[S].,1995.199-201.
  • 2赵金铎.中医证候鉴别诊断学[M].北京:人民卫生出版社,1996.49.

共引文献14

同被引文献14

  • 1石珺,文秀英,胡衍园,许明旺,陈斌.复方桑椹对2型糖尿病肾脏病变疗效的实验研究[J].中国中西医结合杂志,2003,23(S1):131-133. 被引量:7
  • 2胡衍园,文秀英,石珺,许明望.五龙克糖口服液对2型糖尿病大鼠胰岛β细胞的保护作用[J].中国中西医结合杂志,2003,23(S1):123-126. 被引量:4
  • 3Lin J, Hu F B, Rimm E B, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type Ⅱ diabetes mellitus [ J ]. Kidney Int,2006,69(2) : 206 -208.
  • 4Aso Y, Matsumoto S, Fujiwara Y, et al. Impaired fibrinolytic for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1 [J]. Metabolism,2002,51 (4) : 471 -476.
  • 5Zhuo W W, Tao J, Jin P L. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB^db/db mice with type 2 diabetes[J]. Diabetes,2005,54:2328 - 2335.
  • 6Mogensen C E. Managemant of early nephropathy in diabetic patients[J]. Annu Rev Med ,1995 , 46 : 79.
  • 7Ruan X Z, Varghese Z, Powis S H, et al. Dysregulation of LDL recaptor under the influence of inflamematory cytokines: A new pathway for foam cell formation [ J ].Kidney Int,2001,60(5) : 1716 -1725.
  • 8Martinez C A, Ramo R, Gonzalez M T, et al. Dyslipidemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy[J]. Nefrologia,2002,22(Suppl):51 - 58.
  • 9Gotz A K, Boger C A, Hirschmann C, et al. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy[ J]. Eur J Med Res,2005,20,10(4):155 - 160.
  • 10.中药新药治疗消渴病(糖尿病)的临床研究指导原则[S].[S].中华人民共和国卫生部,2002.215-218.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部